Some links will open in the same window, please use the back button to return to this page

Please note that these webinars are not indicated for CE or CME credit.  For CE credit, visit our CE Solutions.
 

Best practices of PET/CT interpretation and referring physician outreach
Presented by Harry Agress Jr., MD, FACR on April 18, 2012
Click anywhere outside of the lightbox to exit the video

The Current Role of PET/CT in Lymphoma
Presented by Michael S. Kipper, MD on February 23, 2012
Click anywhere outside of the lightbox to exit the video

Nuclear Medicine Reimbursement 101-Part 2: Payment for nuclear medicine services and review of PET coverage, coding and reimbursement
Presented by Jim Bietendorf on January 18, 2012
Click anywhere outside of the lightbox to exit the video

PET/CT in Head & Neck Cancer
Presented by Lale Kostakoglu on January 10, 2012
Click anywhere outside of the lightbox to exit the video

Nuclear Medicine Reimbursement 101-Part 1: Reimbursement Basics - Coverage & Coding
Presented by Jim Bietendorf on December 7, 2011
Click anywhere outside of the lightbox to exit the video

Download the slides

PET/CT in Lung Cancer
Presented by Dr. Homer Macapinlac on November 18, 2011
Click anywhere outside of the lightbox to exit the video

Medical Radiation Exposure and Associated Risk
Presented by Satish Nair, Ph.D, CHP, DABMP on October 7, 2011
Click anywhere outside of the lightbox to exit the video

PET/CT in Breast Cancer
Presented by Dr. Maxine Jochelson on September 15, 2011
Click anywhere outside of the lightbox to exit the video

Sharpen your ¹⁸F NaF interpreting skills
Presented by Dr. Kevin Berger
Click anywhere outside of the lightbox to exit the video

For access to clinical reference materials, use the following resources

• Society of Nuclear Medicine Molecular Imaging
• PubMed
• The Journal of American Medical Association
• The New England Journal of Medicine
• MedScape
• Aunt Minnie

• Detection of extra-axillary lymph node involvement with FDG PET/CT in patients with stage II-III breast cancer. Aukema TS, Straver ME, Peeter MJ, Gilhuijs KG, Vogel WV, Rutgers EJ, Olmos RA. Eur J Cancer. 2010 Aug 16.
• Palomar Munoz A. Diagnostic and therapeutic impact of 18F-FDG-PET/CT in patients with suspected breast cancer recurrence. Rev Esp Med Nucl. 2010 May-Jun: 29(3):100-8. Epub 2010 Apr 13.
• Jean H. Lee, et al. The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging. J Nucl Med 2009; 50:569–581.

Cervical

• Grigsby PW. The prognostic value of PET and PET/CT in cervical cancer. Cancer Imaging. 2008 Jul 24;8-146-55.
• Jover R. Role of PET/CT in the evaluation of cervical cancer. Gynecol Oncol. 2008 sep; 110(3 Suppl 2):S55-9.
• Pandharipande, Pari V., et al.  MRI and PET/CT for Triaging Stage IB Clinically Operable Cervical Cancer to Appropriate Therapy: Decision Analysis to Assess Patient Outcomes. Am. J. Roentgenol., Mar 2009; 192: 802 - 814.

Colon

• Fernandez FG, Drebin JA, Linehan DC, Dehdashti F, Siegel BA, Strasberg SM. Five-year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg 2004;240(3):438-447.
• Bamba Y. Management of local recurrence of colorectal cancer: the role of PET/CT. Abdom Imaging. 2010 Jul 27.

Head and neck

• Kubicek GJ. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head and Neck Oncol. 2010 Jul 16; 2:19.

Hypoxia

• Krohn, Kenneth, et al. Molecular Imaging of Hypoxia. Journal of Nuclear Medicine Vol. 49 No. Suppl_2 129S-148S.
• Swanson, Kristin R., et al. Complementary but Distinct Roles for MRI and 18F-Fluoromisonidazole PET in the Assessment of Human Glioblastomas. J Nucl Med 2008, doi:10.2967/jnumed.108.055467.
• Rajendran, Joseph G, et al. Tumor Hypoxia Imaging with [F-18] Fluoromisonidazole Positron Emission Tomography in Head and Neck Cancer. Clin Cancer Res September 15, 2006 12; 5435.

Lung

• Pieterman R.M. Preoperative staging of non-small cell lung cancer with positron emission tomography. N Engl J Med. 2000 Jul 27;343(4):254-61.
• Lardinois D. Staging of non-small lung cancer with -integrated positron emission tomography and computed tomography. N Engl J Med. 2003 Jun 19;348(25):2500-7.
• NCCN Guidelines-Lung

Lymphoma

• Cerci J.J. 18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma. J Nucl Med 2010 Sep Vol. 51:9, pp.1337-1343.
• Cronin CG. Clinical utility of PET/CT in lymphoma. AJR Am J Roentgenol. 2010 Jan; 194(1) W91-W103.

Melanoma

• Harris MT. Impact of 2-deoxy-2(F-18) fluoro-D-glucose Positron Emission Tomography on the management of patients with advanced melanoma. Mol Imaging Biol. 2005 Jul-Aug; 7(4):304-8.

Myeloma

• Fonti, Rosa, et al.18F-FDG PET/CT, 99mTc-MIBI, and MRI in Evaluation of Patients with Multiple Myeloma. Journal of Nuclear Medicine 2008.  Vol. 49 No. 2 195-200.  
• Durie, Brian G.M., et al. Whole-Body 18F-FDG PET Identifies High-Risk Myeloma Journal of Nuclear Medicine 2002: Vol. 43 No. 11 1457-1463.

Ovarian

• Bhosale P. Clinical utility of positron emission tomography/computed tomography in the evaluation of suspected recurrent ovarian cancer in the setting of normal CA-125 levels. Int J Gynecol Cancer. 2010 Aug;20 (6):936-44.
• Prakash P, Cronin CG, Blake MA. Role of PET/CT in ovarian cancer. AJR AM J Roentgenol 2010 Jun;194(6):W464-70.

Prostate

• Even-Sapir, Einat, et al. The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT. J Nucl Med 2006; 47:287–297.

Radiation therapy

• Macapinlac H. Clinical applications of positron emission tomography/computed tomography treatment planning. Semin Nucl Med 2008; 38:137-140.
• MacManus M, Nestle U, Rosenzweig KE, et al. Use of PET and PET/CT for radiation therapy planning: IAEA expert report 2006-2007. Radiother Oncol 2008;91(1):85-94.

Skeletal metastases

• Brenner, Winfried. PET Imaging of Osteosarcoma. J Nucl Med 2003; 44:930–942.
• Bridges, Robert L, et al. An Introduction to Na18F Bone Scintigraphy: Basic Principles, Advanced Imaging Concepts, and Case Examples. J Nucl Med Technol 2007; 35:64–76.
• Even-Sapir, Einat. Imaging of Malignant Bone Involvement by Morphologic, Scintigraphic, and Hybrid Modalities. J Nucl Med 2005; 46:1356–1367.
• Even-Sapir, Einat, et al. Assessment of Malignant Skeletal Disease: Initial Experience with 18F-Fluoride PET/CT and Comparison Between 18F-Fluoride PET and 18F-Fluoride PET/CT.J Nucl Med 2004; 45:272–278.
• Even-Sapir, Einat, et al.  The Detection of Bone Metastases in Patients with High-Risk Prostate Cancer: 99mTc-MDP Planar Bone Scintigraphy, Single- and Multi-Field-of-View SPECT, 18F-Fluoride PET, and 18F-Fluoride PET/CT. J Nucl Med 2006; 47:287–297.
• Grant, Frederick D, et al. Skeletal PET with 18F-Fluoride: Applying New Technology to an Old Tracer. J Nucl Med 2008; 49:68–78.
• Lee, Jean H, et al. The Role of Radiotracer Imaging in the Diagnosis and Management of Patients with Breast Cancer: Part 1—Overview, Detection, and Staging. J Nucl Med 2009; 50:569–581.
• Schirrmeister, Holger, et al. Sensitivity in Detecting Osseous Lesions Depends on Anatomic Localization: Planar Bone Scintigraphy Versus 18FPET. J NucI Med1999; 40:1623-1629.
• Schirrmeister, Holger, et al. Prospective Evaluation of the Clinical Value of Planar Bone Scans, SPECT, and 18F-Labeled NaF PET in Newly Diagnosed Lung Cancer. J Nucl Med 2001; 42:1800–1804.

Other

• Fletcher JW. Recommendations on the use of 18F-FDG PET in oncology. J Nucl Med. 2008 Mar; 49(3):480-508.

Some links will open in the same window, please use the back button to return to this page

Some links will open in the same window, please use the back button to return to this page

Additional and customizable marketing materials